Secukinumab
- CAS No.
- 1229022-83-6
- Chemical Name:
- Secukinumab
- Synonyms
- AIN457;AIN 457;AIN-457;Secukinumab;Secukinumab (anti-IL-17A);Research Grade Secukinumab;Research Grade Secukinumab(DHH28802)
- CBNumber:
- CB12744217
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD01092388
- MOL File:
- Mol file
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| CAS DataBase Reference | 1229022-83-6 |
| FDA UNII | DLG4EML025 |
| NCI Drug Dictionary | secukinumab |
| ATC code | L04AC10 |
Secukinumab Chemical Properties,Uses,Production
Uses
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].
Clinical Use
Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis
Drug interactions
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid.
IC 50
IL-17A
Metabolism
The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.
References
[1] Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. DOI:10.1007/s40265-016-0602-3
[2] Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. DOI:10.1007/s40265-016-0602-3
[3] Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. DOI:10.1002/glia.22637
Secukinumab Preparation Products And Raw materials
Raw materials
Preparation Products
Secukinumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32432 | 58 |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10242 | 58 |
| HONG KONG IPURE BIOLOGY CO.,LIMITED | 86 18062405514 18062405514 | ada@ipurechemical.com | CHINA | 3461 | 58 |
| Hefei Hirisun Pharmatech Co., Ltd | +8615056975894 | shawn@hirisunpharm.com | CHINA | 9911 | 58 |
| Wuhan Golt Biotech Co., Ltd. | +8615389281203 | maria@goltbiotech.com | China | 970 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Hubei KDG Web Science&Technology Co., Ltd | 18672314556 +8618672314556 | sales@kdg-tech.com | China | 933 | 58 |
| XI'AN TIANGUANGYUAN BIOTECH CO., LTD. | China | 995 | 58 | ||
| Wuhan Sunrise Technology Development Co., Ltd. | 27-027-83314682 13554138826 | whsrtech@vip.163.com | China | 245 | 62 |
View Lastest Price from Secukinumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-09-11 | Secukinumab
1229022-83-6
|
US $147.00-711.00 / mg | 99.10% | 10g | TargetMol Chemicals Inc. |
-
- Secukinumab
1229022-83-6
- US $147.00-711.00 / mg
- 99.10%
- TargetMol Chemicals Inc.
